210 related articles for article (PubMed ID: 33617094)
21. Basal cell carcinomas: attack of the hedgehog.
Epstein EH
Nat Rev Cancer; 2008 Oct; 8(10):743-54. PubMed ID: 18813320
[TBL] [Abstract][Full Text] [Related]
22. Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors.
Kudchadkar R; Lewis K; Gonzalez R
Semin Oncol; 2012 Apr; 39(2):139-44. PubMed ID: 22484185
[TBL] [Abstract][Full Text] [Related]
23. Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin.
Makinodan E; Marneros AG
Exp Dermatol; 2012 Nov; 21(11):847-52. PubMed ID: 23163650
[TBL] [Abstract][Full Text] [Related]
24. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
25. Ablative fractional laser treatment reduces hedgehog pathway gene expression in murine basal cell carcinomas.
Pedersen KK; Granborg JR; Lerche CM; Litman T; Olesen UH; Hædersdal M
Lasers Med Sci; 2024 Feb; 39(1):55. PubMed ID: 38308119
[TBL] [Abstract][Full Text] [Related]
26. Nevoid Basal Cell Carcinoma Syndrome:
Martinez MF; Romano MV; Martinez AP; González A; Muchnik C; Stengel FM; Mazzuoccolo LD; Azurmendi PJ
Cells; 2019 Feb; 8(2):. PubMed ID: 30754660
[TBL] [Abstract][Full Text] [Related]
27. Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions.
Urman NM; Mirza A; Atwood SX; Whitson RJ; Sarin KY; Tang JY; Oro AE
PLoS One; 2016; 11(12):e0168031. PubMed ID: 28030567
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma.
Basset-Seguin N; Sharpe HJ; de Sauvage FJ
Mol Cancer Ther; 2015 Mar; 14(3):633-41. PubMed ID: 25585509
[TBL] [Abstract][Full Text] [Related]
29. Vitamin D3 inhibits hedgehog signaling and proliferation in murine Basal cell carcinomas.
Tang JY; Xiao TZ; Oda Y; Chang KS; Shpall E; Wu A; So PL; Hebert J; Bikle D; Epstein EH
Cancer Prev Res (Phila); 2011 May; 4(5):744-51. PubMed ID: 21436386
[TBL] [Abstract][Full Text] [Related]
30. Alternative activation of hedgehog pathway induced by ultraviolet B radiation: preliminary study.
Lesiak A; Sobolewska-Sztychny D; Bednarski IA; Wódz K; Sobjanek M; Woźniacka A; Narbutt J
Clin Exp Dermatol; 2018 Jul; 43(5):518-524. PubMed ID: 29424103
[TBL] [Abstract][Full Text] [Related]
31. Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas.
Albert B; Hahn H
Adv Exp Med Biol; 2014; 810():329-41. PubMed ID: 25207374
[TBL] [Abstract][Full Text] [Related]
32. Hedgehog Signaling and Truncated GLI1 in Cancer.
Doheny D; Manore SG; Wong GL; Lo HW
Cells; 2020 Sep; 9(9):. PubMed ID: 32957513
[TBL] [Abstract][Full Text] [Related]
33. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
34. Relation between sonic hedgehog pathway gene polymorphisms and basal cell carcinoma development in the Polish population.
Lesiak A; Sobolewska-Sztychny D; Majak P; Sobjanek M; Wodz K; Sygut KP; Majsterek I; Wozniacka A; Narbutt J
Arch Dermatol Res; 2016 Jan; 308(1):39-47. PubMed ID: 26590974
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
Von Hoff DD; LoRusso PM; Rudin CM; Reddy JC; Yauch RL; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Mackey HM; Lum BL; Darbonne WC; Marsters JC; de Sauvage FJ; Low JA
N Engl J Med; 2009 Sep; 361(12):1164-72. PubMed ID: 19726763
[TBL] [Abstract][Full Text] [Related]
37. Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma.
Regl G; Neill GW; Eichberger T; Kasper M; Ikram MS; Koller J; Hintner H; Quinn AG; Frischauf AM; Aberger F
Oncogene; 2002 Aug; 21(36):5529-39. PubMed ID: 12165851
[TBL] [Abstract][Full Text] [Related]
38. Chemopreventive efficacy of silibinin against basal cell carcinoma growth and progression in UVB-irradiated Ptch+/- mice.
Paudel S; Raina K; Tiku VR; Maurya A; Orlicky DJ; You Z; Rigby CM; Deep G; Kant R; Raina B; Agarwal C; Agarwal R
Carcinogenesis; 2022 Jun; 43(6):557-570. PubMed ID: 35184170
[TBL] [Abstract][Full Text] [Related]
39. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.
Zuo M; Rashid A; Churi C; Vauthey JN; Chang P; Li Y; Hung MC; Li D; Javle M
Br J Cancer; 2015 Mar; 112(6):1042-51. PubMed ID: 25742482
[TBL] [Abstract][Full Text] [Related]
40. FOXM1 is a downstream target of Gli1 in basal cell carcinomas.
Teh MT; Wong ST; Neill GW; Ghali LR; Philpott MP; Quinn AG
Cancer Res; 2002 Aug; 62(16):4773-80. PubMed ID: 12183437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
